Advice
following an abbreviated submission:
tenecteplase (Metalyse®) is accepted for use within NHSScotland.
Indication under review: in adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.
Tenecteplase offers an additional treatment choice in the therapeutic class of antithrombotic agents.
Download detailed advice279KB (PDF)
Medicine details
- Medicine name:
- tenecteplase (Metalyse)
- SMC ID:
- SMC2697
- Indication:
In adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 November 2024